Ventyx Biosciences Inc VTYX
News
Ventyx Biosciences Announces $27 Million Strategic Investment from Sanofi
Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson’s Disease
Ventyx Biosciences Announces Departure of Chief Financial Officer
Ventyx Biosciences to Participate in Two Upcoming Investor Conferences
Ventyx Biosciences Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Progress
Ventyx Biosciences Announces Results from the Phase 2 Trial of VTX958 in Participants with Moderately to Severely Active Crohn’s Disease
Uber, Datadog stocks gain, Air Products shares lead S&P 500 losers and other stocks on the move
Ventyx Biosciences' stock suffering record plunge after psoriasis treatment trial fails to meet internal efficacy target